Insilico Medicine and SK Biopharmaceuticals Partner to Tackle Neuroimmune Disorders with Generative AI

Strategic Leap: How Insilico Medicine and SK Biopharmaceuticals Deploy Generative AI to Treat Neuroimmune Disorders

Cambridge, MA & Seoul, South Korea – June 22, 2026 — At the BIO 2026 International Convention, Insilico Medicine and SK Biopharmaceuticals announced a strategic alliance to discover and develop drug candidates for neuroimmune disorders. This partnership utilizes generative artificial intelligence to target complex diseases of the central nervous system.

Valued at over $2.5 billion in potential development, regulatory, and commercial milestones—alongside single-digit royalties on net sales—this transaction is Insilico’s largest partnership in the Asia-Pacific (APAC) region to date. SK Biopharmaceuticals will provide an initial $18 million in upfront and near-term milestone payments to secure immediate access to Insilico's proprietary generative chemistry and target discovery systems.

What Are Neuroimmune Disorders?

Definition: Neuroimmune disorders are conditions where the immune system attacks the central or peripheral nervous systems, causing chronic inflammation, tissue damage, and progressive neurodegeneration. Examples include multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and autoimmune encephalitis.

+-----------------------------------------------------------------+
|                   THE BLOOD-BRAIN BARRIER (BBB)                 |
+-----------------------------------------------------------------+
|  [Blood Vessels] ===> [Tight Junctions (BBB Block)] ===> [CNS]  |
|                                                                 |
|  * Traditional Small Molecules: Struggle to cross the BBB.     |
|  * AI-Designed Molecules: Specifically optimized for permeability. |
+-----------------------------------------------------------------+

These disorders present significant challenges for modern drug developers. The blood-brain barrier (BBB)—a highly selective semipermeable border of endothelial cells—blocks over 98% of small-molecule drugs from entering the brain. Consequently, neuroscience drug candidates experience high attrition rates during clinical development.

The economic burden of these diseases continues to grow. Market projections estimate the global neuroimmunology therapy market will reach $63.3 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.6% from its $28.2 billion valuation in 2026. This growth reflects the urgent clinical need for therapies that can penetrate the central nervous system (CNS) and selectively modulate immune pathways without compromising systemic patient safety.

How Insilico Medicine’s Pharma.AI Platform Accelerates Discovery

Definition: Pharma.AI is an end-to-end, deep-learning-based drug discovery suite developed by Insilico Medicine. It integrates target identification (PandaOmics), de novo molecular generation (Chemistry42), and clinical trial outcome prediction (InClinico) to reduce early-stage research timelines from years to months.

  +------------------+      +------------------+      +------------------+
  |   PandaOmics     | ---> |   Chemistry42    | ---> |    InClinico     |
  | (Target ID & Val) |      | (De Novo Design) |      | (Trial Predict)  |
  +------------------+      +------------------+      +------------------+

Traditional drug discovery requires years of target identification and iterative lead optimization. Insilico Medicine, founded by Dr. Alex Zhavoronkov, accelerates this timeline using deep learning, generative adversarial networks (GANs), and transformer models.

By utilizing Pharma.AI, the company routinely nominates preclinical candidates (PCCs) within 12 to 18 months, compared to the industry average of three to four years. This speed is achieved by synthesizing and testing fewer than 200 molecules per program. Since 2021, Insilico has nominated 31 preclinical candidates, with 13 advancing to Investigational New Drug (IND) clearance. A notable validation of this platform occurred in late 2024, when rentosertib (ISM001-055)—an AI-designed small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF)—demonstrated positive safety and efficacy trends in Phase IIa clinical trials.

For the neuroimmune alliance, Insilico will deploy PandaOmics to identify novel therapeutic targets and Chemistry42 to design highly selective, brain-penetrating compounds optimized to cross the blood-brain barrier.

SK Biopharmaceuticals: Scaled CNS R&D and Clinical Execution

Definition: SK Biopharmaceuticals is a global biopharmaceutical enterprise specializing in the research, development, and commercialization of therapies for central nervous system (CNS) disorders. The company is known for bringing cenobamate (Xcopri), an anti-seizure medication, from discovery to FDA approval and independent commercialization.

Under the leadership of President and CEO Donghoon Lee, SK Biopharmaceuticals is expanding its pipeline beyond epilepsy into broader neurological and immunological indications. The company's 2026 corporate strategy emphasizes AI-driven research innovation, targeted protein degradation (TPD), and radiopharmaceutical therapies (RPT) to build a competitive advantage in drug discovery.

By partnering with Insilico, SK Biopharmaceuticals aims to apply its translational medicine, clinical trial design, and commercial infrastructure to candidates generated by the Pharma.AI platform. SK Biopharmaceuticals’ commercial pipeline in the United States provides a clear path to market for neuroimmune candidates that successfully navigate clinical development.

Strategic Synergy: Mitigating Risk in Neuroscience Research

The partnership combines computational speed with clinical and commercial scale:

1. Target Identification: Insilico uses PandaOmics to analyze multi-omics data, identifying novel biological nodes that regulate neuroinflammation.
2. Generative Chemistry: Chemistry42 designs small molecules with high selectivity and optimal blood-brain barrier penetration.
3. Preclinical Validation: Insilico performs initial in vitro and in vivo validation to nominate preclinical candidates.
4. Clinical Development: SK Biopharmaceuticals leads IND-enabling studies, regulatory submissions, global clinical trials, and commercialization.

This workflow addresses key failure points in neuroimmune drug discovery, such as off-target toxicity and poor brain bioavailability, before compounds enter expensive clinical trial phases.

The Economic Context of AI-Driven Drug Discovery

The adoption of artificial intelligence in drug discovery represents a structural shift driven by the need to lower research and development costs.

Target identification platforms are expected to hold a 41% market share in 2026, as companies focus on finding novel disease pathways. Historically, bringing a drug to market requires 10 to 12 years and costs over $2.6 billion, with a clinical success rate below 10%. AI-guided pipelines aim to compress these timelines to three to six years, significantly improving early-stage discovery success rates.

Practical Challenges in AI-Driven Drug Discovery

While generative AI offers clear advantages, several operational challenges remain:

• Data Quality: Generative models require high-quality, curated, and diverse biomedical datasets. Inconsistent data can lead to inaccurate target predictions.
• Wet-Lab Validation: Computational designs must be verified through physical laboratory testing to confirm actual biological activity.
• Regulatory Pathways: Regulatory agencies are still updating guidelines for evaluating AI-designed therapies, requiring transparent data sharing and robust clinical validation.

Insilico and SK Biopharmaceuticals address these challenges by pairing computational modeling with experimental validation, ensuring all AI-generated designs are thoroughly tested in biological systems before moving to clinical trials.

Frequently Asked Questions

What are neuroimmune disorders and why are they difficult to treat?

Neuroimmune disorders occur when the immune system mistakenly attacks parts of the nervous system, leading to chronic inflammation and cellular damage. They are difficult to treat because the blood-brain barrier blocks most therapeutic compounds from entering the brain, and the biological pathways underlying neuroinflammation are highly complex and variable across patients.

What is the financial structure of the Insilico and SK Biopharmaceuticals agreement?

The agreement features a total potential deal value exceeding $2.5 billion, which includes development, regulatory, and commercial milestone payments. Insilico Medicine will receive $18 million in upfront and near-term payments, and is eligible to receive single-digit royalties on net sales of any successfully commercialized therapies resulting from the partnership.

How does generative AI accelerate the discovery of brain-penetrating drugs?

Generative AI platforms like Chemistry42 analyze chemical space to design novel molecular structures optimized for specific parameters, such as metabolic stability, high target selectivity, and the physical properties required to cross the blood-brain barrier. This computational approach replaces slow, trial-and-error chemical synthesis, reducing preclinical design timelines from years to months.

What specific roles do each company play in this neuroimmune partnership?

Insilico Medicine is responsible for target identification and molecular design using its Pharma.AI platform to deliver validated preclinical candidates. SK Biopharmaceuticals is responsible for preclinical safety testing, translational medicine, global clinical development, regulatory filings, and the ultimate commercialization of successful candidates.

Featured image by Pixabay on Pexels